Bioengineering and biotechnology

MIT researchers have developed a non-invasive, wearable pacemaker that stimulates the heart using ultrasound, writes Physics World reporter Tami Freeman. “For cardiac pacing, we envisage that the final goal of NUP [Non-Invasive Ultrasound Pacemaker] technology is to be a permanent alternative to a long-term implanted pacemaker,” says Prof. Xuanhe Zhao. “More broadly, we are interested in expanding ultrasound-enabled bioelectronic medicine beyond cardiac pacing toward other organs and therapeutic applications where non-invasive, spatially precise modulation could have clinical impact.” 

Writing for Bloomberg, Prof. Simon Johnson and Prof. Elisabeth Reynolds describe how the U.S. can maintain its technological leadership by investing in research focused on critical minerals, semiconductors, biotechnology, quantum computing, drones and advanced manufacturing.  “Invention is important, but technological leadership in the 21st century will go to the country that adopts these new ideas rapidly and applies them in clever ways,” Johnson and Reynolds write. “And that will require the U.S. to build vibrant innovation and industrial ecosystems that adopt and diffuse new technologies, including AI.”

Visiting Scientist Alice Stanton speaks with Scientific American reporter Tanya Lewis about her work developing miBrain, a 3D model of the human aimed at helping scientists “better understand neurological diseases such as Alzheimer’s and Parkinson’s so researchers can develop personalized treatments for them.” Says Stanton of the need for stable support for scientific research: “When we have a loved one who gets sick, we want a treatment—we want something to cure them. It doesn’t come out of thin air.”

Boston Globe reporter Robert Weisman spotlights how MIT is “working to drive artificial intelligence forward in sectors where the region is strongest, from biotechnology and robotics to defense and clean energy. It’s also trying to broaden entrepreneurship through a ‘dorm-to-startup’ push, creating a pipeline of support services — from hack-a-thons to venture funding — to help students to start companies between classes.” 

Profs. Elisabeth Reynolds and Simon Johnson joined Tom Keene and Paul Sweeney on Bloomberg Surveillance to discuss their new book, "Priority Technologies: Ensuring U.S. Security and Shared Prosperity," which highlights six key areas where advances in technology can drive the U.S. economy and support national security. “Quantum is the next frontier and opens up billions of dollars of opportunity,” says Reynolds. “Not just for defense and encryption issues, but also across all sorts of applications in financial services and biopharma.” 

Researchers at MIT and elsewhere have developed a compact magnetic mixer to prevent clogs and uneven tissue in 3D bioprinting, reports Aamir Khollam for Interesting Engineering. The device called “MagMix,” works to “keep bio-inks uniform throughout the entire printing process,” writes Khollam. 

Researchers at MIT have developed microscopic devices that “can travel autonomously through the blood and provide electrical stimulation to precise brain regions,” and could one day be used to treat brain diseases, mental illness, or other parts of the body, reports Zoe Kriegler for Medical Design & Outsourcing. The development of microscopic wireless electronic devices (SWEDs) could “eliminate the need for brain surgery in some cases, decreasing the risk to the patient and the expense of the procedure by hundreds of thousands of dollars,” Kriegler explains. 

Prof. Deblina Sarkar speaks with Forbes reporter William A. Haseltine about her work developing “circulatronics,” microscopic electronics devices that could one day be used to help treat brain diseases. “What we have developed are tiny electronic devices that can travel through body fluids and autonomously find their target regions, with no external guidance or imaging,” explains Sarkar. “They provide very precise electrical stimulation of neurons without the need for surgery.” 

Nature reporter James Mitchell Crow spotlights Prof. Leonard Guarente’s work studying the impact of calorie restriction in life expectancy. Guarente’s research points to “the importance of a set of genes and associated proteins called sirtuins.” Guarente says: “If you make them more active, you extend the lifespan.”  

Prof. Linda Griffith speaks with Science Friday host Flora Lichtman about her work studying endometriosis. “I did a lot of things in the regenerative medicine space. But I had an epiphany that there’s so many chronic and inflammatory disease that we don’t know how to treat so I started building models of human organs and tissues in the lab using what we called microfluidic chips,” Griffith explains. “When I got asked about endometriosis, it was actually a perfect application for this kind of approach because we really need to study the lesions very carefully in the lab in ways that is very hard to study in patients.” 

Prof. Deblina Sarkar speaks with Bloomberg Businessweek Daily reporters Carol Massar and David Gura about her work using microscopic technology to treat and identify health issues. We are building “tiny nanoelectronics chips which can seamlessly integrate with our body and brain,” says Sarkar. “This can diagnose disease or treat diseases which even drugs cannot fix.” 

Boston Business Journal reporter Grant Welker spotlights Biogen's groundbreaking ceremony for its new headquarters in MIT’s Kendall Common development. "This area is the most perfect place to do it, because you have some of the highest levels of ingenuity, innovation and energy around the biotech industry, and not to mention partnerships with academic excellence," said Nicole Murphy, Biogen’s executive vice president for pharmaceutical operations and technology." It was absolutely critical to why we feel we want to be here."

Earlier this week, Biogen celebrated the groundbreaking for the company’s new headquarters in MIT’s Kendall Common development, reports Catherine Carlock for The Boston Globe. “When a company as influential as Biogen breaks ground on the new global headquarters, it is an unmistakable vote of confidence — confidence in Massachusetts, confidence in Cambridge, and confidence in Kendall Square, and confidence in the future," said MIT President Sally Kornbluth. “It is on us, on us in Massachusetts, to find new ways to make sure this amazing ecosystem can maintain its record of trailblazing science and transformative treatments and cures.”

Biogen will move its headquarters to a new facility at 75 Broadway in MIT’s Kendall Common development, reports Greg Ryan and Hannah Green for the Boston Business Journal. “The lease is one of the most significant life sciences real estate transactions in Greater Boston,” they write. 

Biogen will move its headquarters to MIT’s Kendall Common development in 2028, reports Catherine Carlock and Jonathan Saltzman for The Boston Globe. “Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century,” says Governor Maura Healey. “We are thrilled to see them begin a new era in our state.”